London Cancer is part of the national cancer vanguard in the NHS England’s New Care Models programme. The aim of the cancer vanguard is to address gaps in health and wellbeing, care, quality and funding, through testing new models that can be rapidly adopted and scaled across the NHS.

Our local vanguard site, led by University College London Hospitals (UCLH) in a system leadership role and supported by all trusts and clinical commissioning groups (CCGs) in our geography, is working jointly with two other cancer vanguard sites that together comprise the national cancer vanguard: RM Partners in west London and Greater Manchester Cancer.

Being part of the national cancer vanguard continues our partnership approach to developing greater accountability for the outcomes of whole pathways of cancer care. It is very much aligned with the ambitions articulated in NHS England’s Five Year Forward View, which focuses on preventing disease, improving earlier diagnosis and addressing variation in practice and access to care.

London Cancer’s Professor Kathy Pritchard-Jones has been appointed as Chief Medical Officer (CMO) of the UCLH Cancer Collaborative, where she is responsible for clinical leadership and is an integral part of the cancer vanguard governance board. Professor Pritchard-Jones will retain her role as CMO of London Cancer and will lead London Cancer’s further development as a key component of the cancer vanguard.

Download the last minutes of the London Cancer transitional board here. For access to previous minutes please email us.

London Cancer is committed to working together across the whole of London with our equivalent organisation in south east London. You can find links to our cancer vanguard partners and Manchester Cancer below.